Navigation Links
EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198
Date:10/25/2007

Significant Survival Advantage Shown in Lung Cancer Model

ROCKVILLE, Md., Oct. 25 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presentation of interim Phase 1 pharmacokinetic results for its antimitotic agent, ENMD-1198, together with preclinical antitumor activity results. The data were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held this week in San Francisco, California.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Pharmacokinetic results demonstrate that once a day orally-administered ENMD-1198 has good pharmacokinetic (PK) parameters in cancer patients participating in a Phase 1 clinical study. In the first four cohorts of the dose-escalation trial in advanced cancer patients, ENMD-1198 demonstrated dose proportional PK exposures across the range of 5-30 mg/m2. ENMD-1198, a new chemical entity (NCE) based on a modified chemical structure of 2- methoxyestradiol (2ME2), was designed to decrease metabolism while retaining 2ME2's multiple mechanisms of action, including inducing apoptosis, disrupting microtubules, and inhibiting HIF-1alpha.

ENMD-1198 was evaluated in a preclinical model of non-small cell lung cancer (NSCLC) and demonstrated a three-fold increase in survival compared to Cisplatin, an approved agent for the treatment of this disease. Approximately 80% of the ENMD-1198 treated models remained on study until tumor dissemination evaluation. In prior preclinical stud
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Clinical Results From EntreMeds Panzem NCD and Taxol Breast Cancer Study Presented at ASCO
2. Phase 2 Results for EntreMeds Panzem NCD Brain Cancer Study Presented at ASCO
3. EntreMeds Aurora Kinase Inhibitor Induces Tumor Regression in Preclinical Models
4. EntreMed Presents Preclinical Data for MKC-1 in Hematological Cancers
5. EntreMed Presents Multi-Mechanism Results for ENMD-1198 at AACR Annual Meeting
6. EntreMed Presents Multi-Mechanism Antitumor Data for ENMD-1420 in Preclinical Models
7. EntreMed Presents Mechanism Data for Its Three Lead Oncology Compounds
8. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
9. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014 This report analyzes the worldwide markets for ... Product Segments: SPECT Systems (Includes SPECT and SPECT/CT systems), and ... separate comprehensive analytics for the US, Canada ... , Asia-Pacific , Latin America ... are provided for the period 2013 through 2020. Also, a ...
(Date:9/16/2014)... 2014 This report analyzes the worldwide markets for ... Parasiticides, Vaccines, Anti-Infectives, Medicinal Feed Additives, and Others. The report ... Animals. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period 2013 ...
(Date:9/16/2014)... , Sept. 16, 2014  ROX Medical ... an international multi-center, prospective, randomized, controlled, blinded endpoint ... of arterial hypertension. The CONTROL-HTN trial, NCT01642498, evaluated the ... a fixed connection between a central artery and ... treatment of hypertension. The primary outcomes are reduction ...
Breaking Medicine Technology:Global Nuclear Medicine Imaging Equipment Industry 2Global Nuclear Medicine Imaging Equipment Industry 3Global Nuclear Medicine Imaging Equipment Industry 4Global Nuclear Medicine Imaging Equipment Industry 5Global Nuclear Medicine Imaging Equipment Industry 6Global Nuclear Medicine Imaging Equipment Industry 7Global Nuclear Medicine Imaging Equipment Industry 8Global Nuclear Medicine Imaging Equipment Industry 9Global Nuclear Medicine Imaging Equipment Industry 10Global Nuclear Medicine Imaging Equipment Industry 11Global Nuclear Medicine Imaging Equipment Industry 12Global Nuclear Medicine Imaging Equipment Industry 13Global Nuclear Medicine Imaging Equipment Industry 14Global Nuclear Medicine Imaging Equipment Industry 15Global Nuclear Medicine Imaging Equipment Industry 16Global Nuclear Medicine Imaging Equipment Industry 17Global Nuclear Medicine Imaging Equipment Industry 18Global Nuclear Medicine Imaging Equipment Industry 19Global Nuclear Medicine Imaging Equipment Industry 20Global Nuclear Medicine Imaging Equipment Industry 21Global Nuclear Medicine Imaging Equipment Industry 22Global Nuclear Medicine Imaging Equipment Industry 23Global Nuclear Medicine Imaging Equipment Industry 24Global Nuclear Medicine Imaging Equipment Industry 25Global Nuclear Medicine Imaging Equipment Industry 26Global Animal Medication Industry 2Global Animal Medication Industry 3Global Animal Medication Industry 4Global Animal Medication Industry 5Global Animal Medication Industry 6Global Animal Medication Industry 7Global Animal Medication Industry 8Global Animal Medication Industry 9Global Animal Medication Industry 10Global Animal Medication Industry 11
(Date:9/16/2014)... 16, 2014 (HealthDay News) -- Although magnesium sulfate is ... preterm delivery, new research suggests it won,t provide any ... effects of magnesium sulfate given to pregnant women, researchers ... behavioral, growth or functional outcomes among those children when ... old. The new findings don,t negate the fact ...
(Date:9/16/2014)... as part of breast conservation is the current ... (HR+) invasive breast cancer. A new study by ... that combination may not be necessary for all ... results, which Fox Chase researchers presented at the ... on Sunday, September 14, suggest that low-risk patients ...
(Date:9/16/2014)... DC (PRWEB) September 16, 2014 Programs ... potentially yield hundreds of billions of dollars in savings ... report by the Commonwealth Fund. To help spur these ... seeking up to 10 collaborative groups from across the ... 1.0 ( http://bit.ly/1wo4gsa ) - a handbook designed to ...
(Date:9/16/2014)... Silver Spring, Md. (PRWEB) September 16, 2014 ... University of Colorado Anschutz Medical Campus and Children’s ... 2014. PHA is the country’s leading pulmonary hypertension association ... hypertension (PH) – a disease of the lungs that affects ... heart failure. Without treatment, mean survivability is only 2.8 years. ...
(Date:9/16/2014)... HealthDay Reporter TUESDAY, Sept. 16, 2014 ... objective scientific way to diagnose major depression in adults, a ... nine genetic indicators (known as "RNA markers") in the blood. ... cognitive behavioral therapy, one of the most common and effective ... Northwestern University researchers report. Depression affects nearly 7 percent ...
Breaking Medicine News(10 mins):Health News:Researchers Don't See Long-Term Benefits From Drug for Preemies 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 3Health News:NQF Seeks Field Testing Groups for Population Health Guide 2Health News:NQF Seeks Field Testing Groups for Population Health Guide 3Health News:Help Fight Pulmonary Hypertension at the Colorado PH in the Park 2014 2Health News:Blood Test Spots Adult Depression: Study 2Health News:Blood Test Spots Adult Depression: Study 3
... , ARLINGTON, Va., Sept. 3 ... Services Office of Inspector General (OIG) ignored the substantial costs ... to seniors and people with disabilities who require mobility assistance. ... Supplier Acquisition Costs and Services" and dated August 2009. , ...
... , AARP Brings the Health Reform Facts ... Minn., Sept. 3 Grab your corn kernels and get ready to cast ... you to take part in the national health reform debate right here at ... lower healthcare costs, make health care more accessible, improve Medicare or lower prescription ...
... rate seems no higher than with seasonal flu , ... have died of complications from the H1N1 swine flu ... least 36 children younger than 18, a new government ... who died had at least one chronic high-risk "neurodevelopmental ...
... costs, study says , THURSDAY, Sept. 3 ... system are more likely to postpone treatment, potentially hurting ... a new study suggests. , Researchers surveyed 401 Baltimore ... attitudes toward the health care system, including doctors, hospitals ...
... 3 Reportlinker.com announces that a new market research report is ... Liver Disease Treatments: The Global Market , ... , , This Report: , ... liver disease treatments, with market forecasts through 2014 , , ...
... As millions of teens head back to school, many will be ... Teens are at a greater risk of than any other age group ... Many of those crashes could be avoided with proper education, says The ... education programs. , , NRSF spokesperson David Reich said ...
Cached Medicine News:Health News:Federal Study on Power Wheelchair Costs in Medicare Is Misleading and Ignores Costs of Required Services for Beneficiaries 2Health News:Federal Study on Power Wheelchair Costs in Medicare Is Misleading and Ignores Costs of Required Services for Beneficiaries 3Health News:Visit AARP's 'Kernels for Healthcare Reform' and Cast Your Vote 2Health News:Swine Flu Poses Risk to Kids With Neurological Conditions 2Health News:Swine Flu Poses Risk to Kids With Neurological Conditions 3Health News:Swine Flu Poses Risk to Kids With Neurological Conditions 4Health News:Mistrust May Cause People to Put Off Treatment 2Health News:Reportlinker Adds Liver Disease Treatments: The Global Market Report 2Health News:Reportlinker Adds Liver Disease Treatments: The Global Market Report 3Health News:Reportlinker Adds Liver Disease Treatments: The Global Market Report 4Health News:Reportlinker Adds Liver Disease Treatments: The Global Market Report 5Health News:Reportlinker Adds Liver Disease Treatments: The Global Market Report 6Health News:Reportlinker Adds Liver Disease Treatments: The Global Market Report 7Health News:Reportlinker Adds Liver Disease Treatments: The Global Market Report 8Health News:Reportlinker Adds Liver Disease Treatments: The Global Market Report 9Health News:Reportlinker Adds Liver Disease Treatments: The Global Market Report 10Health News:Reportlinker Adds Liver Disease Treatments: The Global Market Report 11Health News:Reportlinker Adds Liver Disease Treatments: The Global Market Report 12Health News:Back to School Brings Risks to Young Drivers; Traffic Crashes Leading Cause of Teen Death, Says National Road Safety Foundation 2
... Reticulocyte Stain is an aqueous ... use in manual methods of ... has a one year shelf ... and can be used in ...
... Liquichek ToRCH Plus IgM Controls ... problems in your ToRCH IgM ... your test results. Liquichek ToRCH ... perfect complement to Liquichek ToRCH ...
... Plus Control is a bilevel ... the performance of the most ... assays. A weak positive and ... to monitor the performance of ...
Liquichek Unassayed Chemistry Control (Human) is a comprehensive, stable, liquid product designed to monitor general and special chemistry tests....
Medicine Products: